3 MedTech Stocks to Grab Now for a Strong 2025 This article highlights three MedTech stocks poised for growth in 2025 Barchart · Dec 9, 2024
Would you have your legs broken to make yourself taller? The men who go through hell for a little extra height The procedure can cost £80,000 – but increasing numbers of people are putting themselves through leg-lengthening surgery. What drives them to do it? And is it worth the pain and potential complications? The Guardian - UK · Nov 9, 2022
NuVasive Earnings Perspective: Return On Invested Capital According to Benzinga Pro, during Q1, NuVasive (NASDAQ:NUVA) earned $19.20 million, a 152.27% increase from the preceding quarter. NuVasive's sales decreased to $290.76 million, a 3.75% change since Q4. Benzinga · May 18, 2022
4 Analysts Have This to Say About NuVasive Analysts have provided the following ratings for NuVasive (NASDAQ:NUVA) within the last quarter: Benzinga · May 6, 2022
NuVasive: Q1 Earnings Insights NuVasive (NASDAQ:NUVA) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:10 PM. Here's what investors need to know about the announcement. Earnings NuVasive beat estimated earnings by 38.46%, reporting an EPS of $0.54 versus an estimate of $0.39. Benzinga · May 4, 2022
Earnings Outlook For NuVasive NuVasive (NASDAQ:NUVA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that NuVasive will report an earnings per share (EPS) of $0.39. Benzinga · May 3, 2022
NuVasive: Q4 Earnings Insights NuVasive (NASDAQ:NUVA) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings NuVasive missed estimated earnings by 16.67%, reporting an EPS of $0.4 versus an estimate of $0.48. Benzinga · Feb 23, 2022